| 标题： | 原发性肝癌诊疗指南之肝内胆管癌诊疗共识 |
| title： | Chinese Expert Consensus on management of intrahepatic cholangiocarcinoma |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 从事肝内胆管癌诊疗和健康管理的相关人士 |
| Guide users： | This guideline is aimed for whom engaged in the diagnosis, treatment and healthcare management of intrahepatic cholangiocarcinoma. |
| 证据分级方法： | 本规范参照的循证医学证据等级按照《牛津循证医学中心2011版》进行分级。 |
| Evidence grading method： | The level of evidence was graded according to the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. |
| 制定单位： | 中国抗癌协会肝癌专业委员会胆管癌协作组 |
| Formulating unit： | Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group |
| 注册时间： | 2022-04-27 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN249 |
| Registration number： | |
| 指南制订的目的： | 原发性肝癌主要包括肝细胞癌、肝内胆管和 HCC-ICC 混合型 3 种不同病理学类型。其中肝内胆管癌占原发性肝癌10-15%，其发病机制、生物学行为、组织学形态、治疗方法以及预后等方面与肝癌差异较大。2010年，美国癌症联合委员会发布的第七版TNM分期系统正式将肝内胆管癌从肝癌中分离出来。为了更加细致地指导肝内胆管癌诊疗的临床实践、改善肝内胆管癌患者预后，中国抗癌协会胆管癌协作组审查肝内胆管癌治疗相关证据，结合肝内胆管癌临床实际，撰写了临床诊疗共识。 |
| Purpose of the guideline： | In order to guide the clinical practice of intrahepatic cholangiocarcinoma diagnosis and treatment in a more detailed manner and improve the prognosis of patients with intrahepatic cholangiocarcinoma. The Chinese Society of Liver Cancer (CSLC) Cholangiocarcinoma Cooperative Group reviewed all the evidence related to the treatment of intrahepatic cholangiocarcinoma, and came into consensus to standardize the diagnosis and treatment of intrahepatic cholangiocarcinoma. |
最新注册
